Burns Matteson Capital Management LLC Makes New $67,000 Investment in Bioventus Inc. (NYSE:BVS)

Burns Matteson Capital Management LLC bought a new stake in Bioventus Inc. (NYSE:BVS) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 11,629 shares of the company’s stock, valued at approximately $67,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. LSV Asset Management purchased a new stake in shares of Bioventus during the first quarter worth about $1,170,000. Bailard Inc. acquired a new position in shares of Bioventus in the 4th quarter valued at approximately $307,000. Kennedy Capital Management LLC boosted its stake in shares of Bioventus by 66.8% during the 1st quarter. Kennedy Capital Management LLC now owns 120,134 shares of the company’s stock valued at $625,000 after buying an additional 48,111 shares during the last quarter. Hillsdale Investment Management Inc. bought a new stake in shares of Bioventus in the 4th quarter worth about $145,000. Finally, Jump Financial LLC acquired a new stake in shares of Bioventus in the 4th quarter valued at about $122,000. Institutional investors and hedge funds own 62.94% of the company’s stock.

Insider Buying and Selling

In related news, SVP Anthony D’adamio sold 11,308 shares of the business’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $5.84, for a total transaction of $66,038.72. Following the transaction, the senior vice president now directly owns 81,630 shares of the company’s stock, valued at $476,719.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CFO Mark Leonard Singleton sold 13,753 shares of Bioventus stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $5.84, for a total transaction of $80,317.52. Following the completion of the sale, the chief financial officer now directly owns 63,114 shares in the company, valued at approximately $368,585.76. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Anthony D’adamio sold 11,308 shares of the stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $5.84, for a total value of $66,038.72. Following the completion of the transaction, the senior vice president now owns 81,630 shares in the company, valued at approximately $476,719.20. The disclosure for this sale can be found here. In the last 90 days, insiders sold 40,184 shares of company stock valued at $230,591. Company insiders own 32.90% of the company’s stock.

Bioventus Price Performance

Shares of BVS traded up $1.83 during mid-day trading on Tuesday, hitting $8.09. The company’s stock had a trading volume of 1,192,419 shares, compared to its average volume of 313,374. Bioventus Inc. has a fifty-two week low of $2.82 and a fifty-two week high of $8.12. The stock has a market capitalization of $640.45 million, a price-to-earnings ratio of -23.11 and a beta of 0.84. The firm has a 50-day moving average price of $6.53 and a 200 day moving average price of $5.52. The company has a debt-to-equity ratio of 1.63, a current ratio of 1.53 and a quick ratio of 0.97.

Bioventus (NYSE:BVS) last released its quarterly earnings results on Tuesday, May 7th. The company reported $0.07 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.12. The business had revenue of $129.46 million during the quarter, compared to analyst estimates of $115.51 million. Bioventus had a positive return on equity of 11.91% and a negative net margin of 4.14%. On average, research analysts predict that Bioventus Inc. will post 0.27 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Canaccord Genuity Group boosted their price objective on Bioventus from $7.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, May 8th.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.